The telomerase reverse transcriptase (TERT) promoter, an important element of telomerase expression, has emerged as a target of cancer-specific mutations. Originally described in melanoma, the mutations in TERT promoter have been shown to be common in certain other tumor types that include glioblastoma, hepatocellular carcinoma, and bladder cancer. To fully define the occurrence and effect of the TERT promoter mutations, we investigated tumors from a well-characterized series of 327 patients with urothelial cell carcinoma of bladder. The somatic mutations, mainly at positions −124 and −146 bp from ATG start site that create binding motifs for E-twenty six/ternary complex factors (Ets/TCF), affected 65.4% of the tumors, with even distribution across different stages and grades. Our data showed that a common polymorphism rs2853669, within a preexisting Ets2 binding site in the TERT promoter, acts as a modifier of the effect of the mutations on survival and tumor recurrence. The patients with the mutations showed poor survival in the absence [hazard ratio (HR) 2.19, 95% confidence interval (CI) 1.02-4.70] but not in the presence (HR 0.42, 95% CI 0.18-1.01) of the variant allele of the polymorphism. The mutations in the absence of the variant allele were highly associated with the disease recurrence in patients with Tis, Ta, and T1 tumors (HR 1.85, 95% CI 1.11-3.08). The TERT promoter mutations are the most common somatic lesions in bladder cancer with clinical implications. The association of the mutations with patient survival and disease recurrence, subject to modification by a common polymorphism, can be a unique putative marker with individualized prognostic potential.
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TERT mutations | cancer genetics | transcription factors | noncoding mutations | reporter assays T he human telomerase reverse transcriptase (TERT) gene encodes the catalytic reverse transcriptase subunit of telomerase that maintains telomere length (1) . Increased telomerase activity is perceived to be one of the hallmarks of human cancers, and the transcriptional regulation of the TERT gene is the major cause of its cancer-specific activation (2, 3) . The TERT promoter has been shown to be the most important element of telomerase expression because it harbors binding sites for numerous cellular transcriptional activators and repressors that directly or indirectly regulate the gene expression (4) . In addition, the high GC content around the transcription start site of the TERT promoter confers epigenetic regulation through methylation and chromatin remodeling (5, 6) .
We previously described a high-penetrant disease segregating single-nucleotide germ-line mutation in the TERT promoter in a large melanoma family (7) . The A > C (T > G) mutation at position −57 bp (from the ATG start site; Chr 5:1295161 hg19 coordinate) resulted in creation of a new binding motif GGAA/T for E-twenty six (Ets) transcription factors and a general binding CCGGAA/T motif for ternary complex factors (TCF) (8) . Simultaneous screening of the TERT promoter for somatic mutations in melanoma tumors by us and others resulted in detection of highly recurrent and mutually exclusive somatic mutations mainly at two residues at −124 (1295228) and −146 (1295250) bp from the ATG start site in the TERT promoter (7, 9, 10) . The C > T (G > A) transition at both sites also resulted in creation of the Ets/TCF binding motifs. A concurrent study on cancer cell lines indicated the possibility of mutations being present in cancers other than melanoma (10) . The occurrence of the TERT promoter mutations in a range of tumors in certain cancer types has now been confirmed (11) .
In this study, we investigated a large series of 327 patients with well-characterized tumors from urothelial cell carcinoma of bladder for mutations in the TERT promoter. We observed that the common TERT promoter mutations affected two-thirds of the tumors and were spread across all stages and grades, suggesting that the mutations are early events in bladder carcinogenesis. We also assessed the association of those recurrent TERT promoter mutations with patient survival and disease recurrence.
Significance
This study shows that the telomerase reverse transcriptase (TERT) promoter mutations, which create de novo E-twenty six/ ternary complex factors (Ets/TCF) transcription binding sites, besides being the most common somatic genetic lesions, influence both survival and disease recurrence in bladder cancer patients. The effect of the TERT promoter mutations on both survival and recurrence is modified by a common polymorphism within the preexisting Ets binding site in the TERT promoter. The data were supported by the results from reporter assays carried out in two urothelial carcinoma cell lines. The findings of the study suggest that the TERT promoter mutations in conjunction with the common polymorphism have potential of being used as clinical biomarkers in bladder cancer.
Results
We observed that two nucleotide positions at −124 and −146 bp from ATG start site accounted for over 99% of all of the detected mutations in TERT promoter. The −124C > T (G > A) mutation (Fig. S1 ) was the most frequent alteration that was detected in 175 (53.5%) tumors. In three tumors the nucleotide change involved a C > A (G > T) tranversion at the −124 position. An additional 38 (11.6%) tumors carried the −146C > T (G > A) mutation (Fig. S1 ). One bladder tumor carried a −57A > C (T > G) mutation (Fig. S1) , previously detected as a causal mutation in a melanoma pedigree (7) . The mutations at −57, −124, and −146 bp were mutually exclusive and resulted in creation of a general CCGGAA/T binding motif for Ets/TCF transcription factors (Fig. S2) . Four tumors, in addition to two recurrent mutations, also carried other changes within the amplified region of the TERT promoter (Table S1 ). One tumor (D:078) in addition to the −146C > T (G > A) mutation had on the same allele a single nucleotide (G/C) deletion at −129 bp (1295233 ; Table S1 and Fig. S1 ). The deletion resulted in depletion of a Sp1 transcription factor binding site. Sequencing of the DNA from corresponding germ-line DNA confirmed that mutations in tumors were somatic (more details are provided in SI Results).
Of 327 tumors, 214 (65.4%) carried a defined mutation in the investigated core TERT promoter region ( Table 1 ). The distribution of mutations in the TERT promoter was even in bladder tumors from stages Tis through T2+, ranging from 60% to 71% (Table 1) The statistical analysis showed an independent association of survival with sex, age at diagnosis, tumor grade, stage, disease categories, presence of node, and metastasis (data not shown). A Cox proportional model, which included age at diagnosis, tumor, node, metastasis status, tumor grade, and treatment, showed a hazard ratio (HR) of 1.34 (95% CI 0.81-2.23) for an overall effect of the mutations on patient survival. The corresponding HR for the survival in patients that were noncarriers of the variant allele of the rs2853669 polymorphism was 2.19 (95% CI 1.02-4.70), and in the carriers, HR was 0.42 (95% CI 0.18-1.01; Table 2 ). The interaction between the mutations and polymorphism was statistically significant (P = 0.05). The effect of the TERT promoter mutations on survival and its modification by the polymorphism was confirmed in Kaplan-Meier models (Fig. 1) . In all subcategories a similar trend of the effect of mutations on patients that did not carry the variant allele was observed (Table 3 and Table S2 ).
The analysis of Tis, Ta, and T1 tumors showed that the TERT promoter mutations in the absence of the variant allele of the polymorphism were associated with statistically significant risk of the disease recurrence ( Fig. S3 ) with an HR of 1.85 (95% CI 1.11-3.08); the association was not statistically significant in the presence of the variant allele (HR 1.14, 95% CI 0.62-1.99). For the patients with TaG1 + TaG2 disease categories, the HR for the risk of the recurrence due to the mutations was 2.53 (95% CI 1.20-5.33) in patients that did not carry the variant allele; the association was not statistically significant in presence of the variant allele (HR 0.80, 95% CI 0.36-1.78; Table 2 and Fig. S4 ).
Luciferase reporter assays were carried out in two urothelial cell carcinoma cell lines, T24 and CLS-439, to determine the effect of the TERT promoter mutations and modulation of the effect by the variant allele of the rs2853669 polymorphism. The results from the assays, carried out in triplicate, showed that the constructs with the variant allele of the polymorphism decreased the promoter activity (t test P = 0.02) compared with the construct with wild-type sequence in both cell lines. Both mutations separately showed twofold to fourfold increased promoter activity compared with wild-type sequences. The introduction of the variant allele of the rs2853669 polymorphism in presence of the mutations resulted in reduction of the promoter activity. The reduction in the activity was statistically significantly in both cell lines (t test; P = 0.03 and 0.05) transfected with the construct with −124C > T mutation/variant allele compared with the construct with only −124C > T mutation. In the construct with −146C > T mutation/variant allele, the reduction in the promoter activity compared with the construct with only −146C > T mutation was moderate and was not statistically significant ( Fig. 2 ).
Discussion
Bladder carcinoma represents the one of the most frequent cancers worldwide (12, 13) . The most common bladder carcinomas are derived from urothelium and are perceived to arise by at least two separate mechanisms. The nonmuscle invasive bladder tumors (Tis, Ta, and T1) account for most of the urothelial carcinomas that are confined to mucosa or submucosa (14) . Remaining urothelial carcinomas are invasive that arise either de novo or from high-grade carcinoma in situ (15, 16) . Low-grade tumors are characterized by frequent mutations in the HRAS and fibroblast growth factor receptor 3 (FGFR3) genes. A majority of high-grade tumors that show propensity to progression to local and distant metastasis contain defects in p53 and/or retinoblastoma tumor suppressors. The altered pathways in the both variants of bladder cancer have been a subject of research for targeted therapy (17, 18) . In this study, we investigated the newly discovered noncoding mutations within the core promoter region of the TERT gene. Two major findings of this study include (i) a high recurrence of the TERT promoter mutations in bladder cancer and (ii) association of the detected mutations with the disease recurrence and patient survival, through an interaction with a common polymorphism.
The frequency of the TERT promoter mutations detected was higher than any earlier reported lesions in any gene in bladder cancer (19) . A role for the mutations in early bladder carcinogenesis can be deduced from the occurrence in almost two-thirds of bladder tumors across all stages and grades. The specificity of all mutations detected in the TERT promoter in creation of Ets/ TCF binding motif alludes to involvement of a strong selection because telomerase expression is crucial in maintenance of cancer cells in an immortalized state (20) . The somatic mutations specifically create CCGGAA/T binding motifs for Ets/TCF, which are distinct from the preexisting GGAA sites in the TERT promoter. The specific mutations detected have been shown to cause twofold to fourfold increased promoter activity in reporter assays (7, 10) . Although in melanoma the −146C > T (G > A) was more frequent than the −124C > T (G > A) mutation, in bladder tumors the latter mutation was predominant (7) . Unlike melanoma, CC > TT tandem mutations were absent in bladder cancer, reflecting etiological differences between the cancer types (21) .
Our data showed an overall tendency of poor survival in the patients that carried the mutations in tumors. Previously, the TERT promoter mutations, with prevalence over 80% in gliobastoma, were associated with poor survival (11) . A stratification of the data in the present study showed that the effect of the mutations on survival in bladder cancer patients was modified by a common polymorphism rs2853669 located within 120-140 bp of the mutational sites. The mutations did not affect survival in the patients that were carriers of the variant allele of the polymorphism. A Cox regression model, which included all factors associated independently with survival including treatment, showed over twofold increased hazard ratio for reduced survival of patients that had the somatic TERT promoter mutations in tumors and were noncarriers of the variant allele. All patients included in the analysis had undergone transurethral resection of bladder tumors; some of them, in addition to the resection, had been treated with combinations of radiotherapy, chemotherapy, and immune therapy. With prevalence of the TERT promoter mutations in two-thirds of bladder cancer, almost one-third of the patients would be vulnerable to an adverse effect on survival according to our data. The nonmuscle invasive lesions, with a propensity to recurrence, are generally not associated with mortality (22) . All four patients in the TaG1 disease category, who had died due to the bladder cancer, had the TERT mutations in their tumors and were noncarriers of the variant allele. The data showed that the mutations were also associated with the disease recurrence in patients with Tis, Ta, and T1 tumors. The effect was more pronounced in the absence of the variant allele than in its presence. In the patients with the TaG1 + TaG2 diseases the presence of the mutations and the noncarrier status for the variant allele was associated with a 2.53 increased risk of the tumor recurrence. The current strategy for follow-up treatment is based on risk stratification, dependent on recurrence and progression scores (14) . In clinical trial, bacillus Calmette-Guérin in combination with IFN alpha-2B has been shown to be effective in reducing the recurrence and progression (23) . Genetic markers can be of utmost use in stratification of at risk patients. The TERT mutations, particularly in the absence of the variant allele of the polymorphism, can potentially be helpful in identifying patients for intravesical therapies, which are critical for management of nonmuscle invasive bladder cancer (24) .
Mechanistically, the modifying effect of the polymorphism was in the expected direction. Although the somatic mutations resulted in the creation the Ets/TCF binding sites, the variant allele of the polymorphism disrupted a preexisting noncanonical Ets2 binding site in the proximal region of the TERT promoter, immediately adjacent to an E-box. Interaction of Ets2 with the binding site on TERT promoter has been shown to involve binding of c-Myc to the E-box in breast cancer cell lines (25) . Mutation of the Ets2 binding site has been shown to inhibit E-box binding of c-Myc. The variant allele of the SNP has previously been shown to be associated with low telomerase and telomere activity in non-small cell lung carcinoma (26) . The reported association of the polymorphisms with risk of inherited susceptibility to breast cancer has been inconsistent; however, the tissue and cellular context could be important for functionality as observed in reporter assays (27) (28) (29) (30) .
Based on the information from the 1000 Genomes database (www.1000genomes.org), the rs2853669 polymorphism is in linkage Fig. 1 . Kaplan-Meier analysis of differences in survival (A) in all patients with and without the TERT promoter mutations; (B) in patients that were noncarriers of the variant allele rs2853669, with and without the mutations; and (C) in patients that were carriers of the variant allele rs2853669, with and without the mutations. The numbers of patients at risk in each category are shown along the curves at years 5, 10, and 15. disequilibrium with four other variants that included a synonymous variant (rs2736098) within exon 2 of the TERT gene and three variants located 1.6-2.7 kb upstream of ATG start site (31) . A recent study on breast and ovarian cancers showed that a haplotype composed of three polymorphisms, rs2736107, rs2736108, and rs2736109, which are in linkage disequilibrium with rs2853669, virtually abolished promoter activity in reporter assays. Paradoxically, the alleles in the haplotype that abolished promoter activity were associated with increased telomere length (32) . It is possible that the protective effect on survival and recurrence by the variant allele of rs2853669 could be a proxy for the variants in linkage disequilibrium. However, a reduction in the mutation-induced promoter activity, due to the variant allele in urothelial carcinoma cell lines in this study, suggests functionality for the rs2853669 polymorphism. The constructs used in the assays did not contain variant alleles for any other polymorphisms in linkage disequilibrium with the rs2853669 polymorphism. The detection of the −57A > C (T > G; 1295161) as a somatic mutation in a bladder tumor, which we earlier reported as a highpenetrant causal mutation in a large melanoma pedigree, reinforces the status of the nucleotide changes in the TERT promoter as bonafide driver mutations. p53 has been shown to repress TERT transcription in a Sp1-dependent manner. One of the tumors with a single nucleotide deletion together with the −146C > T mutation represented a unique case where the targeted mutations resulted in an ablation of as Sp1 repressor element and creation of a new site for Ets/TCF (4, 33) .
The resulting increased expression of telomerase as a consequence of the TERT promoter mutations can be a target for therapy. Several strategies of therapeutic telomerase inhibition, including small molecular inhibitors, immunotherapy, gene therapy, and telomere-and telomerase-associated proteins, in different cancers have entered clinical trials (34) . The telomerase protein is also associated with other biological activities that include enhanced cell proliferation, inhibition of apoptosis, and regulation of DNA damage response and cellular proliferative life span that could be affected by the promoter mutations (35) . At a wider level, the promoter mutations represent a paradigm shift in the trail of missing mutations that could not be accounted through the search confined to coding sequences (36) . In the context of bladder cancer, we show that the mutations affect the survival in a manner that is modified by a common genetic polymorphism located within the same locus. The mutations and the polymorphism in conjunction can potentially be used as clinical biomarkers to predict the patient survival and the disease recurrence. 
Materials and Methods
Patients. A total of 538 patients were registered in the Stockholm region with newly diagnosed bladder neoplasms (urothelial cell carcinomas) in 1995-1996 with 15 y clinical follow-up. All hospitals and urology units in the region participated in the study. Treatment and follow-up were performed according to a standard-of-care program. Tumors were removed from patients, before any treatment, with transurethral resection; snap frozen in liquid nitrogen; and cut in approximately 5-μm-thick sections. The first and last sections were stained and examined for tumor content. Only biopsies with more than 70% tumor were included in the study. Tumor stage was assessed according to modified tumor, node, metastasis (TNM) system suggested by Hall and Prout (37) . The World Health Organization 1999 malignancy grading system was used for tumor grade (38) . Informed consent was obtained from all patients included in the study. The study was approved by the Regional Ethics Committee of Stockholm at Karolinska Institutet.
In this study, 327 patients were included, from whom tumor DNA was either available or amplified successfully in PCR. The treatment data were available for 284 patients. One hundred forty-three patients were treated with transurethral resection of bladder tumor only, whereas other patients received different treatment combinations (Table S3 ).
Mutation Detection. DNA was extracted from tumors and corresponding blood tissues using standard procedures. The core TERT promoter region 343 bp (from the position −278 to +65 from ATG start site) was screened for mutations using PCR and Sanger sequencing (Table S4) as described (7). More details are provided in SI Materials and Methods. Mutations in the p53 gene (exon 5-8) in a subset of the bladder tumors included in this study were determined and described previously (39, 40) .
Statistical Analysis. The associations between the age, sex, p53 mutational status, stage, grade, node, metastasis, TERT promoter mutations, and causespecific survival were determined separately using the Kaplan-Meier method. The cumulative curves for the survival outcome in patients with and without the TERT promoter mutations, before and after stratification into carriers and noncarriers of the variant allele of the rs2853669 polymorphism, were drawn. The differences between the curves were analyzed with log rank test. A Cox proportional hazard regression model was used to determine the association between the TERT promoter mutations, before and after stratification for carriers and noncarriers of the variant alleles of the rs2853669 polymorphism, and cause-specific patient survival. The model was adjusted for sex, age at diagnosis, tumor stage, grade, node, metastasis, and treatment. Five patients with Tis were excluded from survival analysis. A Cox model was also used to determine the association between the TERT promoter mutations and the disease recurrence in patients with noninvasive tumors, both before and after stratification for the variant allele of the polymorphism.
Luciferase Reporter Assays. Luciferase reporter assays were carried out by transfecting two uroithelial carcinoma cell lines, T24 and CLS-439, using different reporter constructs in triplicate. More details about the cell lines, cloning, and reporter assays are provided in SI Materials and Methods.
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Rachakonda et al. 10 .1073/pnas.1310522110 SI Materials and Methods PCR and DNA Sequencing. DNA was extracted from tumors and corresponding blood tissues using standard procedures. The core telomerase reverse transcriptase (TERT) promoter region (from the position +65 to −278 bp) was screened for mutations using PCR and Sanger sequencing. DNA samples from tissues were used as templates for amplification of a 343-bp fragment. Each PCR was carried out with 10 ng DNA as a template in a 10-μL volume containing 50 mM KCl, 0.11 μM each primer (Table S4) , 2.0 MgCl 2 , and 10% (vol/vol) glycerol. The sequencing reactions were performed, after purification of amplified DNA fragments with ExoSapIT (Amersham Biosciences) to remove unused primers, using a dideoxy terminator kit (Big Dye; Applied Biosystems). Each sequencing reaction was carried out in a 10-μL volume using forward and reverse primers separately. The electrophoresis of sequencing reaction products was carried out on an ABI prism 3130XL Genetic Analyzer (Applied Biosystems Inc.). The sequences generated were analyzed in Geneious (www.geneious.com). Amplified DNA from a tumor containing a single base C (G) deletion at position −129 bp and another three DNA samples with more than one mutation were cloned into pcr2.1 Topo-TA vectors and analyzed by Sanger sequencing. The transcription factor binding sites in the TERT promoter were assessed by position weight matrix and relative score method using JASPAR algorithm (1).
Luciferase Reporter Assays. For reporter constructs a 2.5-kbp region of TERT locus (chr5:1294815-1297313) was amplified using genomic DNA. The amplified region included 2,209 bp of promoter, followed by 219 bp of exon 1 and 60 bp of intron 1. The amplicon was cloned into a T-overhang vector (pcr2.1 Topo-TA, Invitrogen). The mutations at the −124 and −146 positions and the variant allele at the −245 position were generated using a Quik-change site-directed mutagenesis kit (Invitrogen). A total of six reporter constructs, with wild-type (WT) sequence, with WT + variant allele for the rs2853669 polymorphism, with −124T(A) mutant, with −124T(A) mutant + variant allele for the rs2853669 polymorphism, with −146T(A) mutant, and with −146T(A) mutant + variant allele for the rs2853669 polymorphism, were generated. All of the plasmid constructs were sequenced by Sanger sequencing to confirm the respective mutations and the variant allele. The TERT insert was restriction digested at BamHI and XhoI sites and subcloned into pGL4.10 promoter-less vector (Promega) between XhoI and BglII sites.
Urothelial carcinoma cell lines T24 and CLS-439 used for the assays are derived from Caucasian 81-y-old female and 61-y-old male patients, respectively. Sequencing results showed that both cell lines endogenously carried −124C > T (G > A) mutation in the TERT promoter. The T24 cell line was a kind gift from Karin Hoppe-Seyler (German Cancer Research Center) (2) . The cell line CLS-439, also a bladder carcinoma cell line, was purchased from CLS Cell Lines Services. The cell lines T24 and CLS-439 were cultured in DMEM and RPMI-1640 media (Gibco), respectively, supplemented with 10% FBS (Gibco). Cells were incubated at 37°C in a humidified atmosphere with 5% CO 2 . The cell lines were authenticated by short tandem repeat profiling or multiplex cell authentication (3) . The DNA extracted from the cell lines was also sequenced to screen for the TERT promoter mutations.
Cells were seeded in six-well plates and cotransfected with Lipofectamine 2000 (Invitrogen), 1 μg of each reporter construct, and 50 ng of pRL-SV40 expression plasmid for Renilla luciferase (Promega). pGL3-control plasmid was used for determining transfection efficiency, and pRL-SV40 was used as an internal control for normalization of luminescence values. pGL3-control and pRL-SV40 express firefly luciferase and Renilla luciferase genes under the thymidine kinase and SV40 promoters, respectively. Promoter-less vector (pGL4. 10[luc2] ) and nontransfected cells were used as negative controls. Cells were harvested for 64 h posttransfection and lysed using 1× passive lysis buffer (Promega), and reporter expression was analyzed using the DualLuciferase Reporter assay system (Promega) in 96-well format. Assays were performed in triplicate wells. Relative luciferase activity was calculated as the ratio of firefly to Renilla luminescence to normalize the variations. For reproducibility, experiments were repeated three times. Statistical differences were determined using two-sided t test, and box plots were plotted in R.
SI Results
Four tumors, in addition to two recurrent mutations, also carried other nucleotide changes within the amplified region of the TERT promoter (Table S1 ). DNA from one tumor (D:078) had a single nucleotide (G/C) deletion at −129 bp (1295233; Table S1 ). Cloning of the amplified product into a T-overhang vector showed that the allele with the deletion also carried the −146C > T (G > A; 1295250; Fig. S1 ). The deletion resulted in depletion of a Sp1 transcription factor binding site (Fig. S2) . One tumor (H:036), in addition to the −124C > T (G > A; 1295228) mutation, also carried a −101C > T (G > A; 1295205) nucleotide change. The two nucleotides changes were in two different alleles. Another tumor (K:085), in addition to the −124C > T (G > A) mutation, also showed a −58C > T (G > A; 1295162) base change, and both mutations were on the same allele. One more tumor (S:048) that had the −146C > T (G > A; 1295250) mutation carried two additional nucleotide changes, −67C > T (G > A; 1295171) and −69G > A (C > T; 1295173), and all of the changes were located on the same allele. None of the additional base changes in H:036, K:085, and S:041 tumors affected or created any known transcriptional binding motifs.
In the Kaplan-Meier model, the effect of the mutations on overall patient survival was not statistically significant (log rank P = 0.33). However, in the patients without variant allele of the rs2853669 polymorphism, the mutations were associated with a statistically significant poor survival (log rank P = 0.05) but not in patients that carried the variant allele (log rank P = 0.37; Fig. 1 ).
The effect of the mutations on patient survival in the absence of the variant allele of the polymorphisms was also observed in all subcategories of the bladder cancer patients (Table 3 and Table  S2 ). In patients aged 70 y or more at diagnosis, the hazard ratio for the effect of the mutations in the noncarriers was 4.19 [95% confidence interval (CI) 1.46-12.06] compared with 0.35 (95% CI 0.11-1.12) in the corresponding carriers (Table 3) . In all other categories a similar trend of the effect of mutations on patients that did not carry the variant allele was observed.
In Kaplan-Meier models for the disease recurrence as outcome, the mutations were associated with statistically significant risk in patients with Tis, Ta, and T1 tumors (log rank P = 0.04). The effect of the mutations on the disease recurrence was enhanced in patients that were noncarriers of the variant allele of the polymorphism (log rank P = 0.02; Fig. S3 ). However, in the carriers of the variant allele the effect on the recurrence was not statistically significant (log rank P = 0.86). Similarly, the KaplanMeier analysis for patients with the TaG1 + TaG2 disease categories showed statistically significant effect of mutations on the disease recurrence in patients that were noncarriers of the variant allele (log rank P = 0.01) and not in the patients that were carriers (log rank P = 0.77; Fig. S4) .
The 1000 Genomes database (www.1000genomes.org) showed that the variant is in linkage disequilibrium (r 2 = 0.5 or more) with four other variants, which include rs2736098 (r 2 = 0.85), a synonymous variant at codon 305 (GCG > GCA; ala > ala) within exon 2 of TERT; rs2736109 (located −1.655 kb upstream of ATG; r 2 = 0.66); rs2736108 (located −2.384 kb upstream of ATG; r 2 = 0.94); and rs2736107 (located −2.750 kb upstream of ATG; r 2 = 0.87). Other Supporting Information Files Table S1 (DOCX)  Table S2 (DOCX)  Table S3 (DOCX)  Table S4 (DOCX) 
